So far, the use of antibodies against the PD-1/PD-L1 axis has shown potent antitumor activities in several cancer types, including lung adenocarcinoma (LUAD), gastric cancer, melanoma, and liver cancer (Sui et al., 2015; Han et al., 2020). The gene discussed is PDCD1; the disease is cancer.